These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 32788242

  • 21. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
    Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM, Alzheimer's Disease Neuroimaging Initiative.
    AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
    [Abstract] [Full Text] [Related]

  • 22. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [Abstract] [Full Text] [Related]

  • 23. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C, Blennow K, Hansson O.
    BMC Neurol; 2020 Jan 09; 20(1):10. PubMed ID: 31918679
    [Abstract] [Full Text] [Related]

  • 24. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.
    Van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, Batrla-Utermann R, Dyer RB, Algeciras-Schimnich A, Knopman DS, Jack CR, Petersen RC.
    Neurology; 2020 Jul 21; 95(3):e256-e267. PubMed ID: 32591471
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.
    JAMA Neurol; 2019 Mar 01; 76(3):264-273. PubMed ID: 30615028
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.
    JAMA Neurol; 2015 Sep 01; 72(9):1029-42. PubMed ID: 26147946
    [Abstract] [Full Text] [Related]

  • 30. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 31. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
    Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW, Alzheimer's Disease Neuroimaging Initiative.
    Neurobiol Aging; 2010 Aug 01; 31(8):1340-54. PubMed ID: 20570401
    [Abstract] [Full Text] [Related]

  • 32. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
    Saddiki H, Fayosse A, Cognat E, Sabia S, Engelborghs S, Wallon D, Alexopoulos P, Blennow K, Zetterberg H, Parnetti L, Zerr I, Hermann P, Gabelle A, Boada M, Orellana A, de Rojas I, Lilamand M, Bjerke M, Van Broeckhoven C, Farotti L, Salvadori N, Diehl-Schmid J, Grimmer T, Hourregue C, Dugravot A, Nicolas G, Laplanche JL, Lehmann S, Bouaziz-Amar E, Alzheimer’s Disease Neuroimaging Initiative, Hugon J, Tzourio C, Singh-Manoux A, Paquet C, Dumurgier J.
    PLoS Med; 2020 Aug 01; 17(8):e1003289. PubMed ID: 32817639
    [Abstract] [Full Text] [Related]

  • 33. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
    Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.
    Alzheimers Res Ther; 2016 Jun 30; 8():25. PubMed ID: 27358067
    [Abstract] [Full Text] [Related]

  • 34. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
    Jang H, Park J, Woo S, Kim S, Kim HJ, Na DL, Lockhart SN, Kim Y, Kim KW, Cho SH, Kim SJ, Seong JK, Seo SW, Alzheimer’s Disease Neuroimaging Initiative.
    Neuroimage Clin; 2019 Jun 30; 24():101941. PubMed ID: 31376643
    [Abstract] [Full Text] [Related]

  • 35. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF, Reinvang I, Selnes P, Grambaite R, Fladby T, Hessen E.
    Brain Behav; 2017 Sep 30; 7(9):e00776. PubMed ID: 28948074
    [Abstract] [Full Text] [Related]

  • 36. CSF Aβ42 and tau biomarkers in cognitively unimpaired Aβ- middle-aged and older APOE ε4 carriers.
    Lim YY, Yassi N, Bransby L, Ayton S, Buckley RF, Eratne D, Velakoulis D, Li QX, Fowler C, Masters CL, Maruff P.
    Neurobiol Aging; 2023 Sep 30; 129():209-218. PubMed ID: 37399739
    [Abstract] [Full Text] [Related]

  • 37. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
    Bonham LW, Desikan RS, Yokoyama JS, Alzheimer’s Disease Neuroimaging Initiative.
    Acta Neuropathol Commun; 2016 Jun 29; 4(1):65. PubMed ID: 27357286
    [Abstract] [Full Text] [Related]

  • 38. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
    Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606
    [Abstract] [Full Text] [Related]

  • 39. Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment.
    Liu M, Paranjpe MD, Zhou X, Duy PQ, Goyal MS, Benzinger TLS, Lu J, Wang R, Zhou Y.
    Theranostics; 2019 Aug 01; 9(17):4959-4970. PubMed ID: 31410194
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.